![](/img/cover-not-exists.png)
Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective
Sumitra THONGPRASERT, Sirana TINMANEE, Unchalee PERMSUWANVolume:
8
Year:
2012
Language:
english
Pages:
9
DOI:
10.1111/j.1743-7563.2012.01528.x
File:
PDF, 423 KB
english, 2012